Developing new immunotherapies to treat metastatic cancer
Toward safe, systemic immunotherapies for treatment of metastatic disease: Developing dendritic cell-biased immunomodulators with precise control over magnitude and timing of immune stimulation
['FUNDING_OTHER'] · YALE UNIVERSITY · NIH-10918256
This study is looking at new ways to boost the immune system to help fight metastatic cancer, especially for patients who haven't had success with current treatments, and it may offer a chance to try out these promising new therapies in clinical trials.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | YALE UNIVERSITY (nih funded) |
| Locations | 1 site (NEW HAVEN, UNITED STATES) |
| Trial ID | NIH-10918256 on ClinicalTrials.gov |
What this research studies
This research focuses on creating innovative immunomodulators that can enhance the immune system's ability to fight metastatic cancer. By targeting dendritic cells, the study aims to improve the effectiveness of existing immunotherapies, particularly for patients who do not respond well to current treatments. The approach involves precise control over the timing and dosage of immune stimulation to minimize side effects while maximizing therapeutic benefits. Patients may have the opportunity to participate in clinical trials that explore these new treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with metastatic cancer who have not responded to existing immunotherapies.
Not a fit: Patients with localized cancer or those who have not been diagnosed with metastatic disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with metastatic cancer, potentially improving survival rates.
How similar studies have performed: Other research has shown promise in enhancing immunotherapy effectiveness through similar approaches, indicating potential for success in this area.
Where this research is happening
NEW HAVEN, UNITED STATES
- YALE UNIVERSITY — NEW HAVEN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BHAGCHANDANI, SACHIN — YALE UNIVERSITY
- Study coordinator: BHAGCHANDANI, SACHIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Patient, Cancer Treatment, Cancers